GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RNST · Mar 31, 2026

RENASANT CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000715072-26-000046Bank
Sequential deposit growth75thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

2.92% · CORE · VALID

Net-income growth95thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

112.51% · CORE · VALID

Interest-income growth85thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

53.46% · CORE · VALID

Cash and equivalents65thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$1.2B · CORE · VALID

Sequential loan growth10thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

-0.39% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History37 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Increased
Previous
0.23%
Current
2.92%
Delta
2.69%
Earnings Growth Increased
Previous
-7.26%
Current
112.51%
Delta
119.76%
Interest Income Growth Increased
Previous
42.18%
Current
53.46%
Delta
11.28%
Liquidity Increased
Previous
$1.1B
Current
$1.2B
Delta
$146.3M
Loan Growth Decreased
Previous
0.13%
Current
-0.39%
Delta
-0.53%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.